Affimed N.V. (AFMDQ)
Develops cancer-fighting drugs that train immune cells to attack tumors.
$0.00+0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-99.6%
The outlook
AFMDQ trades at the very bottom of its 52-week range, far below both its 50- and 200-day moving averages. Analyst coverage appears minimal or unavailable. The current data reflects a stock under significant pressure with no near-term technical support visible.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
$1,639
52-wk high
$0.05
52-wk low
$0.00
50-day avg
$0.00
200-day avg
$0.00
Trailing P/E
—